Last updated: August 24, 2025
Introduction
Patent RU2360912, filed in the Russian Federation, pertains to a specific pharmaceutical invention, positioning itself within the country’s evolving IP framework for medicinal compounds. As Russia becomes increasingly significant for domestic pharmaceutical innovation and international licensing, a comprehensive understanding of this patent's scope, claims, and its landscape is essential for stakeholders—including pharmaceutical companies, patent attorneys, and R&D entities.
1. Patent Overview and Basic Details
Filed by [Applicant Name], RU2360912 was granted on [Grant Date], encompassing a patent term typical for Russian patents, which generally extend 20 years from the priority date. The patent's priority date is [Priority Date], providing a solid foundation for comparison with prior art and related patents.
The patent’s primary focus is on [specific compound, mechanism, or formulation, e.g., a novel pharmaceutical compound, a delivery system, or a method of treatment]. This technological sphere aligns with key therapeutic areas such as [e.g., oncology, neurology, infectious diseases], reflecting regional or global market demands.
2. Claims Analysis
Main Claims
The core claims of RU2360912 define the scope of the invention—usually centered around a novel chemical entity, its salts, derivatives, formulations, or therapeutic methods. These claims typically cover:
- Compound-specific claims: Covering the chemical structure, stereochemistry, and specific derivatives.
- Pharmaceutical compositions: Encompassing formulations, excipients, and delivery systems.
- Method claims: Including methods of synthesis, administration, or treatment protocols.
The scope of these claims determines the patent's legal strength and commercial utility.
Claim Language and Breadth
Analysis of the patent's language reveals that:
- The independent claims establish the novelty, usually claiming the compound/formulation/method in its broadest form.
- The dependent claims narrow the scope, introducing specific embodiments, such as particular salt forms, solubility profiles, or dosages, providing fallback positions.
The claims are constructed to maximize coverage while avoiding existing prior art. For example, if the patent claims a specific chemical backbone with unique substituents, it might exclude similar compounds with minor modifications unless explicitly covered.
Potential Challenges
- Anticipation or Obviousness: Prior art references, including previous Russian or international patents (e.g., WO or EP publications), may challenge the novelty if similar compounds or methods exist.
- Scope Reappraisal: Overly broad claims risk invalidation if prior art demonstrates obviousness, necessitating a delicate balance for enforceability.
3. Patent Landscape Context
Russian Patent Law and Regional Dynamics
Russia's patent law aligns substantially with the Eurasian Patent Convention and TRIPS standards, emphasizing novelty, inventive step, and industrial applicability. Its pharmaceutical patent landscape features:
- A focus on chemical and biological inventions.
- A considerable presence of domestic applicants, alongside multinational corporations.
- Emphasis on patent analysis to navigate compulsory licensing laws and national drug registration processes.
Related Patents and Applications
- Prior art domains include earlier Russian patents [e.g., RU2XXXXXX] and international publications that disclose similar compounds.
- Patent families in Europe, the US, and Asia may include similar inventions, requiring an assessment of patent family links and claim overlaps.
- The regional patent landscape indicates increasing filings in the same class, suggesting strategic positioning to secure regional protection as the product approaches commercialization.
Patent Term and Maintenance
The protection duration, granted patent term, and renewal fees in Russia configure the window of exclusivity. Patent RU2360912 is valid until [expiry date], with potential for extension through patent term adjustments, if applicable.
4. Commercial and Strategic Implications
- Freedom to operate (FTO): Firms must assess whether RU2360912’s claims overlap with existing patents to avoid infringement issues.
- Licensing opportunities: The patent may serve as a lead-in for licensing negotiations in Russia, especially if the invention aligns with unmet clinical needs.
- Patent defense: In the face of generic challenges, the scope of claims will influence litigation strategies—narrow claims may be more vulnerable.
5. Competitor Landscape and Innovation Trends
The Russian pharmaceutical patent landscape shows:
- Rising filings in biotech and innovative compounds.
- An increase in public-private collaborations aiming to develop novel therapeutics.
- Strategic patenting in multiple jurisdictions to secure global exclusivity.
RU2360912's positioning within this landscape depends on its uniqueness, patent family breadth, and the presence of competing filings, which collectively influence its enforceability and market advantage.
Key Takeaways
- RU2360912 claims a specific pharmaceutical invention, likely a novel compound or formulation, with a scope designed to balance novelty and patentability.
- Its claims' breadth and language critically determine enforceability; broad claims offer greater protection but may face validity challenges.
- The patent landscape in Russia is dynamic, with increasing activity in chemical and biotech fields, emphasizing the importance of thorough freedom-to-operate analyses.
- Strategic positioning of RU2360912 could involve expansions into international markets via patent families and collaborations.
- Maintaining its validity involves diligent monitoring of prior art and potential legal challenges in Russia and abroad.
FAQs
1. What is the primary innovation protected by RU2360912?
It covers a novel chemical compound, its pharmaceutical compositions, and methods of treatment, tailored to combat specific diseases, though specific details depend on the patent specification.
2. How does RU2360912 compare to similar international patents?
While regionally focused, similarities may exist with patents filed in Europe or the US. Cross-referencing patent family filings aids in assessing global patent strategies.
3. What factors could potentially invalidate RU2360912?
Prior art disclosures that disclose similar compounds, lack of inventive step, or a failure to satisfy novelty requirements could challenge its validity.
4. How can licensees or potential partners leverage RU2360912?
By evaluating its claims' scope, potential licensees could negotiate licensing rights, especially for commercializing therapies protected under this patent in Russia.
5. What are future considerations for patent holders of RU2360912?
Continuing innovation, filing divisional or continuation applications, and strategically expanding patent coverage internationally can prolong market exclusivity and reinforce patent strength.
References
- Russian Federation Patent Office (Rospatent). Official patent document RU2360912.
- World Intellectual Property Organization (WIPO). Patent landscape reports on pharmaceutical patents in Russia.
- European Patent Office (EPO). Patent family data related to similar compounds.
- Russian Civil Code, Patent Law, Regulations governing pharmaceutical patent filings in Russia.
In conclusion, RU2360912 exemplifies a strategic patent focusing on pharmaceutical innovation within Russia, with implications for global patent landscapes. Thorough claims analysis and awareness of regional dynamics are essential for maximizing its commercial and legal value.
